Please provide your email address to receive an email when new articles are posted on . “The DESTINY-Lung study evaluated trastuzumab deruxtecan, a HER2 antibody drug conjugate in patients with HER2 ...
Please provide your email address to receive an email when new articles are posted on . Megan Kruse, MD, a breast medical oncologist at Cleveland Clinic, spoke with Healio about results from her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback